同济大学附属第十人民医院 普通外科 副主任
Deputy Director of General Surgery, Tenth People's Hospital Affiliated to Tongji University
同济大学附属第十人民医院 肝胆胰外科 主任
Director of Department of Hepato-Pancreato-Biliary Surgery，Tenth People's Hospital of Tongji University
中国抗癌协会肝癌专委会青委会 副主任委员
Deputy Director of Youth Committee of Chinese Society of Liver Cancer
中国临床肿瘤学会胆道肿瘤专家委员会 委员
Member of Biliary Tract Cancers of Chinese Society of Clinical Oncology
中国抗癌协会胆道肿瘤专家委员会 委员
Member of the Biliary Tract Tumor Expert Committee of the Chinese Anti-Cancer Association
中国研究型医院学会普外专家委员会 委员
Member of the General Surgery Expert Committee of the Chinese Society of Research Hospitals
中国医师协会整合医学分会普外科专委会 委员
Member of Holistic Integrative Society of General Surgery of Chinese Medical Doctor Association
中国医师协会临床精准医疗专委会青委会 委员
Member of Youth Committee of Chinese Society of Clinical Precision Medicine
上海市医学会普通外科分会 青年委员
Youth Member of Shanghai Society of General Surgery
上海市抗癌协会肿瘤生物治疗专业委员会 委员
Member of tumor Biological Treatment Committee of Shanghai Anti-Cancer Association
李俊，同济大学附属第十人民医院主任医师、教授、博士生导师，任同济大学附属第十人民医院普外科副主任、肝胆胰外科主任。毕业于第二军医大学，从事肝胆外科临床和科研工作近30年，曾任我国肝胆外科开拓者吴孟超院士医疗工作秘书。
主持国家科技重大专项子课题、国家自然科学基金项目等重要科研课题10余项，发表SCI论文60余篇，其中以通讯/第一作者在J Clin Oncol、JAMA Oncol、Lancet Gastroenterol & Hepatol和Ann Surg等杂志发表论文30余篇。获上海市科技进步一等奖、国之名医·青年新锐、人民好医生 (肝胆肿瘤领域)·优秀典范、上海优秀青年学术带头人、上海卫生系统“银蛇奖”和第二军医大学“银手术刀”等荣誉。
李俊教授长期从事肝胆胰恶性肿瘤的外科临床治疗和研究工作。针对肝内胆管癌诊治尚不成熟预后极差，肝细胞癌的复发防治尚缺乏个体化的现状，建立了基于临床病理的个体化预后预测系统，藉此可实现外科治疗和复发防治的精准决策，显著提高术后生存率。
(1) 建立肝内胆管癌 (ICC) 的“中国列线图”，有助于该病个体化外科治疗体系的形成。1) 创建首个ICC个体化分期-列线图 (一种可预测单个病人预后的计算标尺)，发表在临床肿瘤杂志 (J Clin Oncol，影响因子45.3)，被国际同行称为“中国列线图”。国际肿瘤分期权威机构-美国癌症联合会根据该成果对ICC分期做出重要修改，首次将肿瘤体积纳入该分期。2) 通过利用影像组预测模型在肝切除术前评估淋巴结转移的风险，明确不同肝切除方式 (解剖性 vs. 非解剖性) 的适合人群和建立复发性ICC再切除的选择评分等优化了ICC的外科诊治技术。上述工作形成基于风险评估的个体化治疗模式，使ICC肝切除术后的5年生存率从既往的20%提高到35.2%。
(2) 提出基于复发风险预测的肝癌 (HCC) 抗复发新策略，促进复发防治水平的提高。1) 建立基于HCC微血管侵犯的个体化预测评估体系，协助临床作出兼顾提高疗效和减少创伤的精准治疗决策。成果发表在美国医学会会刊·肿瘤学 (JAMA Surg，影响因子16.9)，外科学年鉴 (Ann Surg，影响因子9.0)和欧洲肿瘤杂志 (Eur J Cancer，影响因子8.4) 等期刊，成果获上海市科技进步一等奖。2) 开展随机对照临床研究 (RCT)，提供高级别的HCC复发防治循证医学证据。通过多中心RCT建立了国际首个肝细胞癌肝切除术后靶向放射免疫抗复发技术 (使用针对HAb18G/CD147抗原的131I-美妥昔单抗)，使抗原阳性的患者早期复发率降低35.9%，发表在柳叶刀·胃肠肝病学 (Lancet Gastroenterol & Hepatol，影响因子35.7)。通过目前唯一RCT，发现对于肿瘤直径>3 cm且甲胎蛋白>200 ng/mL的复发性肝细胞癌，再次肝切除疗效显著优于射频消融，发表在美国医学会会刊·肿瘤学 (JAMA Oncol，影响因子28.4)。
Li Jun, chief physician, professor, and doctoral supervisor of the Tenth People's Hospital affiliated to Tongji University, is the deputy director of the General Surgery Department and the director of the Hepatobiliary and Pancreatic Surgery Department of the Tenth People's Hospital affiliated to Tongji University. He graduated from the Second Military Medical University and has been engaged in clinical and scientific research in hepatobiliary surgery for nearly 30 years. He was once the medical secretary of Academician Wu Mengchao, the pioneer of hepatobiliary surgery in my country.
He has presided over more than 10 important scientific research projects such as sub-projects of major national science and technology projects and National Natural Science Foundation projects, and published more than 60 SCI papers, including more than 30 papers published as the corresponding/first author in journals such as J Clin Oncol, JAMA Oncol, Lancet Gastroenterol & Hepatol, and Ann Surg. He has won the first prize of Shanghai Science and Technology Progress, the title of National Famous Doctor·Young Newcomer, the title of People's Good Doctor (in the field of hepatobiliary tumors)·Excellent Model, the title of Shanghai Outstanding Young Academic Leader, the "Silver Snake Award" of Shanghai Health System and the "Silver Scalpel" of the Second Military Medical University.
Professor Li Jun has long been engaged in surgical clinical treatment and research of malignant tumors of the liver, biliary and pancreas. In view of the current situation that the diagnosis and treatment of intrahepatic cholangiocarcinoma is immature and the prognosis is very poor, and the recurrence prevention and treatment of hepatocellular carcinoma still lacks individualization, an individualized prognosis prediction system based on clinical pathology has been established, which can achieve accurate decisions on surgical treatment and recurrence prevention and treatment , significantly improve postoperative survival rate.
(1) Establishing a “Chinese nomogram” for intrahepatic cholangiocarcinoma (ICC) will help form an individualized surgical treatment system for this disease. 1) Created the first ICC individualized staging-nomogram (a calculation scale that can predict the prognosis of a single patient), published in the Journal of Clinical Oncology (J Clin Oncol, impact factor 45.3), and was called the "Chinese nomogram" by international peers picture". Based on this result, the American Federation on Cancer, an authoritative international cancer staging organization, made important changes to the ICC staging, including tumor volume into the staging for the first time. 2) Optimizing ICC by using imaging group prediction models to assess the risk of lymph node metastasis before liver resection, clarifying suitable populations for different liver resection methods (anatomical vs. non-anatomical), and establishing a selection score for re-excision of recurrent ICC. surgical diagnosis and treatment techniques. The above work has formed an individualized treatment model based on risk assessment, which has increased the 5-year survival rate after ICC liver resection from the previous 20% to 35.2%.
(2) Propose a new anti-recurrence strategy for liver cancer (HCC) based on recurrence risk prediction to promote the improvement of recurrence prevention and treatment. 1) Establish an individualized prediction and evaluation system based on HCC microvascular invasion to assist clinical practice in making precise treatment decisions that take into account both improved efficacy and reduced trauma. The results were published in journals such as JAMA Surg (impact factor 16.9), Annals of Surgery (Ann Surg, impact factor 9.0), and Eur J Cancer (impact factor 8.4). The results were awarded Shanghai First Prize of Municipal Science and Technology Progress Award. 2) Carry out randomized controlled clinical studies (RCT) to provide high-level evidence-based medical evidence for the prevention and treatment of HCC recurrence. Through multi-center RCT, the world's first targeted radioimmunoassay anti-recurrence technology (using 131I-metuximab targeting HAb18G/CD147 antigen) after liver resection for hepatocellular carcinoma was established, which reduced the early recurrence rate of antigen-positive patients by 35.9% %, published in The Lancet Gastroenterol & Hepatol (impact factor 35.7). Through the only RCT currently available, it was found that for recurrent hepatocellular carcinoma with a tumor diameter >3 cm and alpha-fetoprotein >200 ng/mL, repeat liver resection is significantly more effective than radiofrequency ablation. It was published in the Journal of the American Medical Association·Oncology ( JAMA Oncol, impact factor 28.4).
